Enhertu nabs priority review for NSCLC as AstraZeneca and Daiichi Sankyo continue charting a blockbuster course

Max Gelman

Senior Editor

As AstraZeneca and Daiichi Sankyo continue to outline their blockbuster plans for the antibody-drug conjugate Enhertu, the FDA is giving them an assist.

Regulators awarded …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Enhertu nabs priority review for NSCLC as AstraZeneca and Daiichi Sankyo continue charting a blockbuster course

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bristol Myers prunes pipeline amid new round of cost cuts

Pfizer hires Novartis oncology exec to steer its cancer ambitions

AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal

J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmaker

Bristol Myers launches fresh round of major cost cuts in bid to get ahead of patent cliff

Updated: Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer's, heart failure and eczema

En­her­tu nabs pri­or­i­ty re­view for NSCLC as As­traZeneca and Dai­ichi Sankyo con­tin­ue chart­ing a block­buster course

Senior Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Enhertu nabs priority review for NSCLC as AstraZeneca and Daiichi Sankyo continue charting a blockbuster course